Switzerland· 56148001
Somatuline Autogel 60 mg, Depot-Injektionslösung in einer Fertigspritze
A lanreotide product, registered in Switzerland by IPSEN Pharma Schweiz GmbH and dispensed under Swissmedic category A. The same ATC class is registered in 17 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Lanreotide is registered in 17 of 19 countries.
Countries holding a registration under ATC H01CB03 (lanreotide), each read from that country’s own register.
- This record: Switzerland
- 10 of them publish a price we can compare per daily dose
Lanreotide · ATC H01CB03
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lanreotide costs, country by country.
Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.
- Switzerland: $44.46 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Lanreotide · price per daily dose (3 mg)
USD · FX 28 Sept 2026
- FR France$53.80
- CH Switzerland$44.46
The record
At a glance
- Manufacturer
- IPSEN Pharma Schweiz GmbH
- Country
- Switzerland (CH)
- ATC code
- H01CB03
- ATC class
- Lanreotide
- Defined daily dose
- 3 mg, P
- Swissmedic category
- A
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
157 interactions on record for lanreotide.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lanreotide · interactions on record
157 records
- 2 severe
- 151 moderate
- 4 minor
Most severe, free to view
- LonafarnibA16AX20severe
- PexidartinibL01EX15severe
- LiraglutidA08AX02moderate
- SemaglutidA08AX03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under H01CB03
Lanreotide, as other registers publish it.
- ItalyIPSTYLIPSEN S.P.A.
- ItalyIPSTYLIPSEN S.P.A.
- ItalyIPSTYLIPSEN S.P.A.
- DenmarkIpstyl AutogelInstitut Produits Synthése (Ipsen) AB
- DenmarkIpstyl AutogelInstitut Produits Synthése (Ipsen) AB
- NorwayIpstyl AutogelInstitut Produits Synthèse (IPSEN) AB
- NorwayIpstyl AutogelInstitut Produits Synthèse (IPSEN) AB
- DenmarkIpstyl AutogelInstitut Produits Synthése (Ipsen) AB
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/afccaa0e-f43f-4053-8bec-f0f40d02442e GET /v1/drugs/afccaa0e-f43f-4053-8bec-f0f40d02442e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about lanreotide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.